| DIRECT COMPETITOR COMPARISON | |
| NVO | LLY | PFE | SNY | Industry | | Market Cap: | 39.48B | 42.97B | 150.01B | 103.03B | 163.44M | | Employees: | 28,497 | 40,500 | 81,800 | 98,213 | 95 | | Qtrly Rev Growth (yoy): | 11.30% | 6.80% | -2.90% | 8.50% | 20.50% | | Revenue (ttm): | 10.29B | 21.11B | 45.82B | N/A | 46.74M | | Gross Margin (ttm): | 79.57% | 82.33% | 86.61% | 75.20% | 68.58% | | EBITDA (ttm): | 3.56B | 7.74B | 21.31B | N/A | -7.12M | | Oper Margins (ttm): | 29.92% | 30.97% | 37.42% | N/A | 2.25% | | Net Income (ttm): | 2.19B | -216.00M | 8.09B | N/A | N/A | | EPS (ttm): | 3.60 | -0.197 | 1.204 | N/A | -0.17 | | P/E (ttm): | 18.39 | N/A | 15.44 | N/A | 18.38 | | PEG (5 yr expected): | 1.19 | 4.05 | 5.99 | 2.54 | 1.01 | | P/S (ttm): | 3.82 | 2.03 | 3.22 | N/A | 4.37 |
|
| LLY = Eli Lilly & Co. | | PFE = Pfizer Inc. | | SNY = Sanofi-Aventis | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.40 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | PFE | | INSIDE WASHINGTON: Stream of WH health care visits
Thu 4:11pm -
AP | | • | PFE | | Pfizer Increases R&D Commitment in China
Thu 3:09am -
at Seeking Alpha | | • | PFE | | AP IMPACT: A stream of WH health care visits
Wed, Nov 25 -
AP | | • | LLY | | Sitting Atop An Earnings Powder Keg
Wed, Nov 25 -
at Forbes.com | | • | PFE | | CORRECTED - US sees rise in secondary infections after flu
Wed, Nov 25 -
at Reuters | | • | LLY | | A Big Upgrade for Amylin Pharmaceuticals
Wed, Nov 25 -
at Motley Fool | | • | PFE | | Prospecting for Stocks: Novartis
Wed, Nov 25 -
at Motley Fool | | • | SNY | | Former chairman in Ratiopharm bid
Wed, Nov 25 -
at FT.com | | • | LLY | | 7 Dividend Divas
Wed, Nov 25 -
at Motley Fool | | • | SNY | | A Schizophrenic Move by Merck?
Wed, Nov 25 -
at Motley Fool | | • | SNY | | Sanofi Expands Regeneron Agreement
Wed, Nov 25 -
Zacks.com | | • | SNY | | Worse Than The NBC-Comcast Deal? No Deal
Wed, Nov 25 -
at Forbes.com | | • | LLY | | Do Good Without Being a Corporate Hotshot
Wed, Nov 25 -
at Motley Fool | | • | SNY | | Making Flu Vaccine: Eggs Aren't the Only Problem
Wed, Nov 25 -
at The Wall Street Journal Online | | • | LLY | | Forgetful patients lift support consultancies
Tue, Nov 24 -
at FT.com | | • | SNY | | Cramer's 'Mad Money' Follow-Up: Nov. 24
Tue, Nov 24 -
at TheStreet.com | | • | SNY | | How Big Pharma Profits from Swine Flu
Tue, Nov 24 -
at BusinessWeek | | | All Headlines for these symbols... |
|
|
|
0.29% Nasdaq 
Competitors
